The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 gene on skeletal muscle glucose uptake depends on obesity: A positron emission tomography study

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4249-4254

  Vänttinen, Markku ^a   Nuutila, Pirjo ^b   Pihlajamäki, Jussi ^a   Hällsten, Kirsti ^b   Virtanen, Kirsi A ^b   Lautamäki, Riikka ^b   Peltoniemi, Pauliina ^b   Kemppainen, Jukka ^b   Takala, Teemu ^b   Viljanen, Antti P M ^b   Knuuti, Juhani ^b   Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; UNCLASSIFIED DRUG; WATER O 15; FATTY ACID;

ADIPOSE TISSUE; ADULT; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MUSCLE PERFUSION; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKELETAL MUSCLE; BLOOD; CROSS-SECTIONAL STUDY; GENETICS; METABOLISM; MIDDLE AGED;

ADIPOSE TISSUE; ADULT; ALLELES; CROSS-SECTIONAL STUDIES; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA;

EID: 23044478560     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0101     Document Type: Article

References (47)

1. Auwerx J 1999 PPAR-γ, the ultimate thrifty gene. Diabetologia 42:1033-1049
2. Fajas L, Fruchart JC, Auwerx J 1998 PPAR-γ3 mRNA: a distinct PPAR-γ mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55-60
3. Sundvold H, Lien S 2001 Identification of a novel peroxisome proliferatoractivated receptor (PPAR)-γ promoter in man and transactivation by the nuclear receptor RORα1. Biochem Biophys Res Commun 287:383-390
4. 12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
5. 12Ala missense mutation. Biochem Biophys Res Commun 241:270-274
6. 12Ala substitution in PPAR-γ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
7. 12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47:1806-1808
8. 12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50:891-894
9. 12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): Divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42:892-895
10. Valve R, Sivenius K, Miettinen R, Pihlajamäki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M 1999 Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708-3712
11. 3-adrenergic receptor and peroxisome proliferator-activated receptor-γ2 genes and obesity. Diabetes Care 24:672-677
12. 12Ala variant: Association with type 2 diabetes and trait differences. Diabetes 50:886-890
13. 12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51:2581-2586
14. 12Ala variant on body mass index: A meta-analysis. J Med Genet 40:773-780
15. Robitaille J, Despres JP, Perusse L, Vohl MC 2003 The PPAR-γ P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 63:109-116
16. Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, Hunter DJ 2003 Interaction between a peroxisome proliferator-activated receptor-γ gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 12:2923-2929
17. 12Ala polymorphism. Diabetes 51:2341-2347
18. 18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest 97:1741-1747
19. Hällsten K, Yki-Järvinen H, Peltoniemi P, Oikonen V, Takala T, Kemppainen J, Laine H, Bergman J, Bolli GB, Knuuti J, Nuutila P 2003 Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obes Res 11:257-265
20. 18F]FDG) and PET in combination with microdialysis. Diabetologia 44:2171-2179
21. Nuutila P 1997 Applications of PET in diabetes research. Horm Metab Res 29:337-339
22. Virtanen KA, Lönnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, Tolvanen T, Knuuti J, Rönnemaa T, Huupponen R, Nuutila P 2002 Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in non-obese and obese humans. J Clin Endocrinol Metab 87:3902-3910
23. Takala TO, Nuutila P, Knuuti J, Luotolahti M, Yki-Järvinen H 1999 Insulin action on heart and skeletal muscle glucose uptake in weight lifters and endurance athletes. Am J Physiol 276:E706-E711
24. 18F]fluoro-deoxy- glucose, and positron emission tomography. Diabetes 49:1084-1091
25. DeFronzo R, Tobin J, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
26. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238
27. Crouzel C, Clark J, Brihaye C 1993 Radiochemistry automation for PET. In: Stocklin G, Pike V, eds Radiopharmaceuticals for positron emission tomography. Dordrecht, The Netherlands: Kluwer Academic; 45-90
28. 2O production system for heart and brain studies. J Labelled Compd Radiopharm 44:S1066-S1068
29. Alenius S, Ruotsalainen U 1997 Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med Mol Imaging 24:258-265
30. Pitkänen OP, Laine H, Kemppainen J, Eronen E, Alanen A, Raitakari M, Kirvela O, Ruotsalainen U, Knuuti J, Koivisto VA, Nuutila P 1999 Sodium nitroprusside increases human skeletal muscle blood flow, but does not change flow distribution or glucose uptake. J Physiol 521:729-737
31. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916
32. Patlak C, Blasberg R 1985 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 5:584-590
33. 18F]fluorodeoxy-glucose in skeletal muscles of obese and non-obese humans. Am J Physiol 279:E1122-E1130
34. Kety S 1960 Theory of blood-tissue exchange and its application to measurement of diffusible substance. Methods Med 8:223-227
35. Ruotsalainen U, Raitakari M, Nuutila P, Oikonen V, Sipila H, Teräs M, Knuuti MJ, Bloomfield P, Iida H 1997 Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J Nucl Med 38:314-319
36. Kadish A, Little R, Sternberg J 1968 A new and rapid method for determination of glucose by measurement of rate of oxygen consumption. Clin Chem 14:116-131
37. Kuzuya H, Blix B, Horwitz D, Steiner D, Rubenstein A 1977 Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 26:22-29
38. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M 1983 A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24:96-99
39. Friedewald W, Levy R, Fredrickson D 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
40. Baron A, Steinberg H, Chaker H, Leaming R, Johnson A, Brechtel G 1995 Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 96:786-792
41. Laakso M, Edelman S, Brechtel G, Baron A 1990 Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844-1852
42. 12Ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism 53:11-16
43. 12Ala polymorphism of the PPAR-γ2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia 44:925-926
44. 12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 50:2172-2176
45. 12Ala polymorphism of the PPAR-γ2 gene regulates weight from birth to adulthood. Obes Res 12:187-190
46. 12AAla polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50:876-881
47. Walczak R, Tontonoz P 2002 PPARadigms and PPARadoxes: expanding roles for PPAR-γ in the control of lipid metabolism. J Lipid Res 43:177-186